{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Refractory+Multiple+Myeloma+%28RRMM%29&page=4", "query": { "condition": "Relapsed Refractory Multiple Myeloma (RRMM)", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 84, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Refractory+Multiple+Myeloma+%28RRMM%29&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+Refractory+Multiple+Myeloma+%28RRMM%29&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T18:32:46.495Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05911321", "title": "Isa-Pom-Dex in Elderly/Frail Subjects With RRMM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Relapse", "Refractory", "Aging", "Co-morbidity" ], "interventions": [ { "name": "Isatuximab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2023-12-05", "completion_date": "2028-03-26", "has_results": true, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-10-07T18:32:46.495Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05911321" }, { "nct_id": "NCT04401020", "title": "First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Malignant" ], "interventions": [ { "name": "SAR442257", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2020-07-24", "completion_date": "2026-05-11", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-07T18:32:46.495Z", "location_count": 3, "location_summary": "Duarte, California • Miami, Florida • Rochester, Minnesota", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04401020" }, { "nct_id": "NCT06171685", "title": "MMRC Horizon One: RRMM (MMRC-099)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapse Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Teclistamab Monotherapy", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Multiple Myeloma Research Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 300, "start_date": "2024-11-17", "completion_date": "2030-07-31", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-07T18:32:46.495Z", "location_count": 13, "location_summary": "Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06171685" }, { "nct_id": "NCT06518551", "title": "Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myeloma", "Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Iberdomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Omar Nadeem, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2024-11-01", "completion_date": "2034-12-31", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-07T18:32:46.495Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06518551" }, { "nct_id": "NCT07084896", "title": "Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Nirogacestat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2020-06-08", "completion_date": "2027-03-11", "has_results": true, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-07T18:32:46.495Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Grand Rapids, Michigan + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07084896" }, { "nct_id": "NCT07681596", "title": "A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed or Refractory Multiple Myeloma" ], "interventions": [ { "name": "AZD4045", "type": "BIOLOGICAL" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2026-07-27", "completion_date": "2031-03-06", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-07T18:32:46.495Z", "location_count": 10, "location_summary": "Duarte, California • Denver, Colorado • Tampa, Florida + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07681596" }, { "nct_id": "NCT05014412", "title": "A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2021-10-07", "completion_date": "2025-12-12", "has_results": true, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-10-07T18:32:46.495Z", "location_count": 35, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Fort Collins, Colorado + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05014412" }, { "nct_id": "NCT03650491", "title": "A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Multiple Myeloma in Relapse", "Multiple Myeloma With Failed Remission" ], "interventions": [ { "name": "FOR46", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fortis Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2019-04-03", "completion_date": "2022-01-31", "has_results": false, "last_update_posted_date": "2022-07-27", "last_synced_at": "2026-10-07T18:32:46.495Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03650491" }, { "nct_id": "NCT04975997", "title": "Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Iberdomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 939, "start_date": "2022-06-23", "completion_date": "2032-06-25", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-07T18:32:46.495Z", "location_count": 43, "location_summary": "Hot Springs, Arkansas • Cerritos, California • Fountain Valley, California + 38 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04975997" }, { "nct_id": "NCT05405166", "title": "SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plasma Cell Myeloma Recurrent" ], "interventions": [ { "name": "Isatuximab IV", "type": "DRUG" }, { "name": "Isatuximab SC", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Paracetamol / Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 531, "start_date": "2022-06-23", "completion_date": "2027-10-22", "has_results": true, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-07T18:32:46.495Z", "location_count": 13, "location_summary": "Aurora, Colorado • Jacksonville, Florida • Plantation, Florida + 10 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Hattiesburg", "state": "Mississippi" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05405166" } ] }